PLEASE NOTE : This is a development system.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Evolocumab - Lipid modification
PAD Profile : Evolocumab - Lipid modification Important
Keywords :
Dyslipidaemia, hyperlipidaemia, lipid modification, high cholesterol, raised cholesterol, Lipid regulating, PCSK9 Inhibitor, heterozygous familial hypercholesterolaemia, non-familial hypercholesterolaemia
Brand Names Include :
Repatha
Important Information :
Restricted to lipidologists only for heterozygous familial and non-familial hypercholesterolaemia.
Traffic Light Status
Status 1 of 1.
Guidelines
The following guidelines are available for this indication.
Other Drugs
- Atorvastatin
- Rosuvastatin calcium
- Simvastatin
- Ezetimibe
- Pravastatin sodium
- Fluvastatin sodium
- Alirocumab
- Fenofibrate
- Bezafibrate
- Ciprofibrate
- Gemfibrozil
- Colesevelam hydrochloride
- Colestyramine
- Bempedoic acid
- Inclisiran
- Icosapent
Other Indications
Additional Documents
Type
Document
Review Date
NICE Technology Appraisal
Committee Recommendations
Date
Committee Name
Narrative
05 October 2016
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
The PCN recommends evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia in line with NICE TA394 (June 2016)
Prescribing will be initiated and treatment continued by specialists with training in lipid management and notification of initiation and continuation of treatment will be via the Blueteq database. Evolocumab will be considered RED on the traffic light system
Associated BNF Codes
02. Cardiovascular System
02.12.00. Lipid-regulating drugs